# EDGAR Filing Document

**Accession Number:** 0001974640
**File Stem:** 0001104659-26-021900
**Filing Date:** 2026-3
**Character Count:** 20551
**Document Hash:** 760998631310e66c21fc83137edea6ef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-021900.hdr.sgml**: 20260302

**ACCESSION NUMBER**: 0001104659-26-021900

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260302

**DATE AS OF CHANGE**: 20260302

**EFFECTIVENESS DATE**: 20260302

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Apogee Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001974640
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 934958665
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-293906
- **FILM NUMBER:** 26703495

**BUSINESS ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 17, SUITE 102B
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453
- **BUSINESS PHONE:** 650-394-5230

**MAIL ADDRESS:**
- **STREET 1:** 221 CRESCENT ST.
- **STREET 2:** BUILDING 17, SUITE 102B
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02453

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Apogee Therapeutics, LLC
- **DATE OF NAME CHANGE:** 20230420

**As filed with the Securities and Exchange Commission on March 2, 2026**

Registration No. 333-

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Apogee Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **93-4958665** |
| (State or Other Jurisdiction of <br> Incorporation or Organization) | (I.R.S. Employer Identification No.) |

---

**221 Crescent St., Building 17, Suite 102b**

**Waltham, MA 02453**

**(650) 394-5230**<br> (Address of Principal Executive Offices, Zip Code)

**Apogee Therapeutics, Inc. 2023 Equity Incentive Plan**

**Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan**

(Full title of the plan)

**Michael Henderson, M.D.**

**Chief Executive Officer**

**221 Crescent St., Building 17, Suite 102b**

**Waltham, MA 02453**

**(650) 394-5230**<br> (Name and address of agent for service)

 

**Copies to:**

---

| | |
|:---|:---|
| **Matthew Batters**<br> **Chief Legal Officer and Secretary**<br> **221 Crescent St., Building 17, Suite 102b**<br> **Waltham, MA 02453**<br> **(650) 394-5230** | **Ryan A. Murr<br> Branden C. Berns<br> Melanie E. Neary<br> Gibson, Dunn & Crutcher LLP<br> One Embarcadero Center, Suite 2600<br> San Francisco, CA 94111<br> (415) 393-8373** |

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting company | ◻ |
|  |  | Emerging growth company | ◻ |

---

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is filed by Apogee Therapeutics, Inc. (the "Company" or the "Registrant"), relating to (i) 3,420,067 shares of its common stock, par value $0.00001 per share (the "Common Stock"), available for issuance pursuant to future awards to eligible persons under the Apogee Therapeutics, Inc. 2023 Equity Incentive Plan (the "2023 Plan") and (ii) 684,013 shares of Common Stock issuable to eligible persons under the Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan (the "ESPP").

The information contained in the Registrant's registration statements on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on [August 28, 2023](https://www.sec.gov/Archives/edgar/data/1974640/000110465923095681/tm2324400d1_s8.htm) (File No. 333-274234), [May 13, 2024](https://www.sec.gov/Archives/edgar/data/1974640/000110465924060211/tm2414093d1_s8.htm) (File No. 333-279354), and [March 3, 2025](https://www.sec.gov/Archives/edgar/data/1974640/000110465925019460/tm257913d1_s8.htm) (File No. 333-285478), together with all exhibits filed therewith or incorporated therein by reference, is hereby incorporated by reference pursuant to General Instruction E to Form S-8 regarding the Registration of Additional Securities, except as amended hereby.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.** **Exhibits.**

---

| | |
|:---|:---|
| <u>Exhibit No.</u> | <u>Exhibit Description</u> |
| [4.1](https://www.sec.gov/Archives/edgar/data/1974640/000155837023015278/apge-20230630xex3d1.htm) | [Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q filed on August 28, 2023).](https://www.sec.gov/Archives/edgar/data/1974640/000155837023015278/apge-20230630xex3d1.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1974640/000155837023015278/apge-20230630xex3d2.htm) | [Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q filed on August 28, 2023).](https://www.sec.gov/Archives/edgar/data/1974640/000155837023015278/apge-20230630xex3d2.htm) |
| [5.1\*](tm267328d1_ex5-1.htm) | [Opinion of Gibson, Dunn & Crutcher LLP.](tm267328d1_ex5-1.htm) |
| [23.1\*](tm267328d1_ex23-1.htm) | [Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.](tm267328d1_ex23-1.htm) |
| [23.2\*](tm267328d1_ex5-1.htm) | [Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).](tm267328d1_ex5-1.htm) |
| [24.1\*](#m_001) | [Power of Attorney (included on signature page hereto).](#m_001) |
| [99.1](https://www.sec.gov/Archives/edgar/data/1974640/000155837023015278/apge-20230630xex10d9.htm) | [Apogee Therapeutics, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 of the Company's Quarterly Report on Form 10-Q filed on August 28, 2023).](https://www.sec.gov/Archives/edgar/data/1974640/000155837023015278/apge-20230630xex10d9.htm) |
| [99.2](https://www.sec.gov/Archives/edgar/data/1974640/000110465923079247/tm2313083d13_ex10-15.htm) | [Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.15 to the Company's Registration Statement on Form S-1/A filed on July 10, 2023).](https://www.sec.gov/Archives/edgar/data/1974640/000110465923079247/tm2313083d13_ex10-15.htm) |
| [107.1\*](tm267328d1_ex-filingfees.htm) | [Filing Fee Table.](tm267328d1_ex-filingfees.htm) |

---

\*Filed herewith.

**SIGNATURES**

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on this 2nd day of March, 2026.

---

| | |
|:---|:---|
| **Apogee Therapeutics, Inc.** | **Apogee Therapeutics, Inc.** |
| By: | /s/ Michael Henderson, M.D. |
| Name: | Michael Henderson, M.D. |
| Title: | Director and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Henderson, M.D. and Matthew Batters, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462 under the Securities Act, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully so or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, the following persons have signed this Registration Statement in the capacities and on the date(s) indicated.

---

| | | |
|:---|:---|:---|
| <u>Signature</u> | <u>Title</u> | <u>Date</u> |
| /s/ Michael Henderson, M.D. | Director and Chief Executive Officer (*Principal Executive Officer*) | March 2, 2026 |
| Michael Henderson, M.D. |  |  |
| /s/ Jane Pritchett Henderson | Chief Financial Officer (*Principal Financial and Accounting Officer*) | March 2, 2026 |
| Jane Pritchett Henderson |  |  |
| /s/ Mark C. McKenna | Chair and Director | March 2, 2026 |
| Mark C. McKenna |  |  |
| /s/ Lisa L. Bollinger, M.D. | Director | March 2, 2026 |
| Lisa L. Bollinger, M.D. |  |  |
| /s/ Jennifer Fox | Director | March 2, 2026 |
| Jennifer Fox |  |  |

---

---

| | | |
|:---|:---|:---|
| /s/ Andrew Gottesdiener, M.D. | Director | March 2, 2026 |
| Andrew Gottesdiener, M.D. |  |  |
| /s/ Peter Harwin | Director | March 2, 2026 |
| Peter Harwin |  |  |
| /s/ William Jones, Jr. | Director | March 2, 2026 |
| William Jones, Jr. |  |  |
| /s/ Tomas Kiselak | Director | March 2, 2026 |
| Tomas Kiselak |  |  |
| /s/ Nimish Shah | Director | March 2, 2026 |
| Nimish Shah |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](tm267328d1_ex5-1img001.jpg)

March 2, 2026

Apogee Therapeutics, Inc.

*Re:* *Registration Statement on Form S-8*

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8, (the "Registration Statement") of Apogee Therapeutics, Inc., a Delaware corporation (the "Company"), to be filed with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offering by the Company of up to (i) 3,420,067 shares (the "2023 Plan Shares") of the Company's Common Stock, par value $0.00001 per share (the "Common Stock"), available for issuance pursuant to the Apogee Therapeutics, Inc. 2023 Equity Incentive Plan (the "2023 Plan") and (ii) 684,013 shares (the "2023 ESPP Shares," and, together with the 2023 Plan Shares, the "Shares") of the Company's Common Stock available for issuance pursuant to the Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP", and, together with the 2023 Plan, the "Plans").

In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of such documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinion set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. As to any facts material to this opinion, we have relied to the extent we deemed appropriate and without independent investigation upon statements and representations of officers and other representatives of the Company and others. We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plans that would expand, modify or otherwise affect the terms of the Plans or the rights or obligations of the participants thereunder.

Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor in accordance with the terms set forth in the Plans, as applicable, as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "DGCL"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption "Legal Matters" in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

Very truly yours,

/s/ Gibson, Dunn & Crutcher LLP

**Gibson, Dunn & Crutcher LLP**

One Embarcadero Center Suite 2600 \| San Francisco, CA 94111-3715 \| T: 415.393.8200 \| F: 415.393.8306 \| gibsondunn.com

## Exhibit 23.1

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in this Registration Statement (Form S-8) pertaining to the Apogee Therapeutics, Inc. 2023 Equity Incentive Plan and the Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan of our reports dated March 2, 2026, with respect to the consolidated financial statements of Apogee Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Apogee Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

Boston, Massachusetts

March 2, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Apogee Therapeutics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | Common stock, par value $0.00001 per share | 457(a) | 3420067 | $69.46 | $237557853.82 | 0.0001381 | $32806.74 |
| 2 | Equity | Common stock, par value $0.00001 per share | 457(a) | 684013 | $59.04 | $40384127.52 | 0.0001381 | $5577.05 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $277941981.34  |  | $38383.79  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $38383.79  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall be deemed to cover any additional shares of common stock, par value $0.00001 per share (the "Common Stock"), of Apogee Therapeutics, Inc. that may be issued pursuant to the Apogee Therapeutics, Inc. 2023 Equity Incentive Plan (the "2023 Plan") and the Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan (the "2023 ESPP") as a result of any stock dividend, stock split, recapitalization or other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged. Represents 3,420,067 shares of Common Stock reserved for issuance under the 2023 Plan. With respect to the Common Stock being registered under the 2023 Plan, the proposed maximum offering price is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and is based on the average of the high and low sale prices of the Common Stock, as quoted on the Nasdaq Stock Market, on February 23, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> Pursuant to Rule 416(a) under the Securities Act, this Registration Statement on Form S-8 shall be deemed to cover any additional shares of Common Stock of Apogee Therapeutics, Inc. that may be issued pursuant to the 2023 Plan and the 2023 ESPP as a result of any stock dividend, stock split, recapitalization or other similar transaction, and any other securities with respect to which the outstanding shares are converted or exchanged. Represents 684,013 shares of Common Stock reserved for issuance under the 2023 ESPP. With respect to the Common Stock being registered under the 2023 ESPP, the proposed maximum offering price is estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act, and is based on 85% of the average of the high and low sale prices of the Common Stock, as quoted on the Nasdaq Stock Market, on February 23, 2026.

---

| | |
|:---|:---|
| | |
| **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | N/A |
| Fee Offset Sources | N/A |

---